Tushar Kotecha
Overview
Explore the profile of Tushar Kotecha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharrack N, Knott K, Gulsin G, Kotecha T, Brown L, Yeo J, et al.
Sci Rep
. 2024 Nov;
14(1):27280.
PMID: 39516499
Metformin is an antihyperglycemic used to treat type 2 diabetes mellitus (T2DM). Patients with T2DM are at increased risk of cardiovascular disease. We explored the association between metformin use and...
2.
Foley M, Rajkumar C, Ahmed-Jushuf F, Simader F, Chotai S, Seligman H, et al.
Circulation
. 2024 Oct;
151(3):202-214.
PMID: 39462291
Background: ORBITA-2 (the Placebo-Controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable...
3.
Netti L, Ioannou A, Martinez-Naharro A, Razvi Y, Porcari A, Venneri L, et al.
Eur J Heart Fail
. 2024 Oct;
PMID: 39422337
Aims: Cardiac amyloidosis (CA) is characterized by deposition of amyloid fibrils within the extracellular space, causing disarray of the myocardial structure and capillary architecture. This study aims to characterize the...
4.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, et al.
JAMA Cardiol
. 2024 Aug;
9(11):982-989.
PMID: 39167388
Importance: Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless...
5.
Brown J, Virsinskaite R, Kotecha T, Steeden J, Fontana M, Karia N, et al.
Eur Heart J Cardiovasc Imaging
. 2024 Aug;
25(12):1712-1720.
PMID: 39159164
Aims: Systemic sclerosis complicated by pulmonary arterial hypertension (SSc-PAH) is a rare condition with poor prognosis. The majority of patients are categorized as intermediate risk of mortality. Cardiovascular magnetic resonance...
6.
Crane J, Joy G, Knott K, Augusto J, Lau C, Bhuva A, et al.
JACC Cardiovasc Imaging
. 2024 Aug;
17(11):1305-1316.
PMID: 39115498
Background: Coronary microvascular function is impaired in patients with obesity, contributing to myocardial dysfunction and heart failure. Bariatric surgery decreases cardiovascular mortality and heart failure, but the mechanisms are unclear....
7.
Simader F, Rajkumar C, Foley M, Ahmed-Jushuf F, Chotai S, Bual N, et al.
J Am Coll Cardiol
. 2024 May;
84(1):13-24.
PMID: 38759906
Background: Placebo-controlled evidence from ORBITA-2 (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina-2) found that percutaneous coronary intervention (PCI) in stable coronary artery disease with...
8.
Knight D, Virsinskaite R, Karia N, Cole A, Maclean R, Brown J, et al.
Rheumatology (Oxford)
. 2024 May;
63(10):2678-2683.
PMID: 38759116
Objectives: Measures of right heart size and function are prognostic in systemic sclerosis-associated pulmonary hypertension (SSc-PH), but the importance of myocardial tissue characterisation remains unclear. We aimed to investigate the...
9.
Rajkumar C, Foley M, Ahmed-Jushuf F, Simader F, Mohsin M, Ganesananthan S, et al.
J Am Coll Cardiol
. 2024 May;
84(1):1-12.
PMID: 38752902
Background: In stable coronary artery disease, 30% to 60% of patients remain symptomatic despite successful revascularization. Perhaps not all symptoms reported by a patient with myocardial ischemia are, in fact,...
10.
Foley M, Rajkumar C, Ahmed-Jushuf F, Simader F, Chotai S, Pathimagaraj R, et al.
Lancet
. 2024 Apr;
403(10436):1543-1553.
PMID: 38604209
Background: The coronary sinus reducer (CSR) is proposed to reduce angina in patients with stable coronary artery disease by improving myocardial perfusion. We aimed to measure its efficacy, compared with...